ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

ClinicalTrials.gov ID: NCT01209078

Public ClinicalTrials.gov record NCT01209078. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

Study identification

NCT ID
NCT01209078
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
84 participants

Conditions and interventions

Interventions

  • GSK1322322 Drug
  • GSK1322322 placebo Drug
  • Linezolid Drug
  • Linezolid placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 16, 2010
Primary completion
Jan 17, 2011
Completion
Jan 17, 2011
Last update posted
Dec 3, 2017

2010 – 2011

United States locations

U.S. sites
7
U.S. states
4
U.S. cities
7
Facility City State ZIP Site status
GSK Investigational Site Anniston Alabama 36207
GSK Investigational Site Chula Vista California 91911
GSK Investigational Site La Mesa California 91942
GSK Investigational Site Long Beach California 90813
GSK Investigational Site Oceanside California 92056
GSK Investigational Site Honolulu Hawaii 96813
GSK Investigational Site West Reading Pennsylvania 19611

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01209078, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 3, 2017 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01209078 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →